MedPath

KANAZAWA UNIVERSITY

KANAZAWA UNIVERSITY logo
🇯🇵Japan
Ownership
Private
Established
1949-05-31
Employees
1K
Market Cap
-
Website
http://www.kanazawa-u.ac.jp

Clinical Trials

113

Active:0
Completed:63

Trial Phases

5 Phases

Phase 1:4
Phase 2:1
Phase 3:2
+2 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (113 trials with phase data)• Click on a phase to view related trials

Not Applicable
104 (92.0%)
Phase 1
4 (3.5%)
Phase 3
2 (1.8%)
Phase 4
2 (1.8%)
Phase 2
1 (0.9%)

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Phase 4
Completed
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
First Posted Date
2016-01-07
Last Posted Date
2021-07-02
Lead Sponsor
Kanazawa University
Target Recruit Count
40
Registration Number
NCT02649465
Locations
🇯🇵

Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

Phase 1
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
First Posted Date
2014-05-30
Last Posted Date
2018-02-05
Lead Sponsor
Kanazawa University
Target Recruit Count
12
Registration Number
NCT02151721
Locations
🇯🇵

Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

🇯🇵

Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo-ken, Japan

🇯🇵

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

and more 2 locations

Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Not Applicable
Conditions
Ischemic Heart Failure
First Posted Date
2012-10-18
Last Posted Date
2017-08-18
Lead Sponsor
Kanazawa University
Target Recruit Count
6
Registration Number
NCT01709279
Locations
🇯🇵

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

Phase 4
Conditions
Type 2 Diabetes Mellitus
Chronic Liver Disease
Interventions
First Posted Date
2011-04-18
Last Posted Date
2011-04-18
Lead Sponsor
Kanazawa University
Target Recruit Count
20
Registration Number
NCT01337440
Locations
🇯🇵

Internal medicine, Kanazawa university hospital, Kanazawa, Ishikawa, Japan

Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells

Not Applicable
Completed
Conditions
Liver Cirrhosis
First Posted Date
2010-02-04
Last Posted Date
2015-09-07
Lead Sponsor
Kanazawa University
Target Recruit Count
4
Registration Number
NCT01062750
Locations
🇯🇵

Kanazawa University Hospital, Kanazawa, Ishikawa, Japan

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.